Isolated hepatic perfusion for patients with liver metastases

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 4, 2014, Pages 180-194

  Reddy, Srinevas K ^a   Kesmodel, Susan B ^a   Alexander, H Richard ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

colorectal cancer liver metastases; isolated hepatic perfusion; melanoma liver metastases; neuroendocrine liver metastases; ocular melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLOXURIDINE; FLUOROURACIL; HEPARIN; IRINOTECAN; LACTATE DEHYDROGENASE; MELPHALAN; MITOMYCIN; OXALIPLATIN; TUMOR NECROSIS FACTOR ALPHA;

ARTERY CATHETER; BALLOON CATHETER; BLOOD CLOTTING TIME; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; DRUG DELIVERY SYSTEM; DRUG INFUSION; EXTRACORPOREAL CIRCULATION; FLOW RATE; HEPATIC ARTERY; HUMAN; HYPERTHERMIC THERAPY; INFERIOR CAVA VEIN; INTERNAL JUGULAR VEIN; ISOLATED HEPATIC PERFUSION; LEIOMYOSARCOMA; LIVER HILUS; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; LIVER VEIN; LIVER VENOOCCLUSIVE DISEASE; LONG TERM CARE; MELANOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL VEIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SARCOMA; SURVIVAL RATE; TUMOR VOLUME; VASCULAR CLAMP; VEIN BLOOD FLOW;

EID: 84904814999     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014529175     Document Type: Review

References (67)

1. Agarwala S. Panikkar R. Kirkwood J. (2004) Phase I / II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 14: 217–222.
2. Aigner K. Walther H. Tonn J. Wenzl A. Hechtel R. Merker G. et al. (1983) First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary. Recent Results Cancer Res 86: 99–102.
3. Alexander H. Bartlett D.L. Libutti S.K. Fraker D.L. Moser T. Rosenberg S.A. (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16: 1479–1489.
4. Alexander H. Jr Bartlett D. Libutti S. Pingpank J. Fraker D. Royal R. et al. (2009) Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 16: 1852–1859.
5. Alexander H. Jr Libutti S. Bartlett D. Pingpank J. Kranda K. Helsabeck C. et al. (2002) Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 95: 730–736.
6. Alexander H.R. Libutti S.K. Bartlett D.L. Puhlmann M. Fraker D.L. Bachenheimer L.C. (2000) A Phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6: 3062–3070.
7. Alexander H. Jr Libutti S. Pingpank J. Bartlett D. Helsabeck C. Beresneva T. (2005) Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 12: 138–144.
8. Alexander H. Jr Libutti S. Pingpank J. Steinberg S. Bartlett D. Helsabeck C. et al. (2003) Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9: 6343–6349.
9. Apple S. Hecht J. Lewin D. Jahromi S. Grody W. Nieberg R. (1999) Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol 30: 123–129.
10. Ausman R. (1961) Development of a technic for isolated perfusion of the liver. N Y State J Med 61: 3393–3397.
11. Beheshti M. Denny D. Jr Glickman M. Bodden W. Marsh J. Strair R. et al. (1992) Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. JVIR 3: 453–458.
12. Benevento A. Boni L. Frediani L. Ferrari A. Dionigi R. (2000) Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 74: 24–29.
13. Bidard F. Tournigand C. Andre T. Mabro M. Figer A. Cervantes A. et al. (2009) Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX 1 study. Ann Oncol 20: 1042–1047.
14. Breedis C. Young G. (1954) Blood supply of neoplasms of the liver. Am J Pathol 30: 969–985.
15. Chamberlain R. Canes D. Brown K. Saltz L. Jarnagin W. Fong Y. et al. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190: 432–445.
16. Chapman P. Hauschild A. Robert C. Haanen J. Ascierto P. Larkin J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
17. Chen H. Hardacre J. Uzra A. Cameron J. Choti M. (1998) Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 187: 88–92.
18. Cohen V. Carter M. Kemeny A. Radatz M. Rennie I. (2003) Metastasis-free survival following treatment for uveal melanoma with either stereotactic radiosurgery or enucleation. Acta Ophthalmol Scand 81: 383–388.
19. Curley S. Newman R. Dougherty T. Fuhrman G. Stone D. Mikolajek J. et al. (1994) Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1: 389–399.
20. de Brauw L. Marinelli A. van de Velde C. Hermans J. Tjaden U. Erkelens C. et al. (1991) Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Res 51: 1694–1700.
21. Eisen T. Trefzer U. Hamilton A. Hersey P. Millward M. Knight R. et al. (2010) Results of a multicenter, randomized, double-blind phase 2 / 3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 116: 146–154.
22. Fiorentini G. Aliberti C. Del C. Tilli M. Rossi S. Ballardini P. et al. (2009 a) Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 23: 131–137.
23. Fiorentini G. Aliberti C. Del C. Tilli M. Rossi S. Ballardini P. et al. (2009 b) Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 23: 131–137.
24. Flaherty K. Robert C. Hersey P. Nathan P. Garbe C. Milhem M. et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107–114.
25. Giantonio B. Catalano P. Meropol N. O'Dwyer P. Mitchell E. Alberts S. et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539–1544.
26. Grover A. Libutti S. Pingpank J. Helsabeck C. Beresnev T. Alexander H. Jr (2004) Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136: 1176–1182.
27. Gruber-Rouh T. Naguib N. Eichler K. Ackermann H. Zangos S. Trojan J. et al. (2013) Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer 134: 1225–1231.
28. Gupta S. Yao J. Ahrar K. Wallace M. Morello F. Madoff D. et al. (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9: 261–267.
29. Hafström L. Holmberg S. Naredi P. Lindnér P. Bengtsson A. Tidebrant G. et al. (1994) Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 3: 103–108.
30. Huppert P. Fierlbeck G. Pereira P. Schanz S. Duda S. Wietholtz H. et al. (2010) Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 74: e38–e44.
31. Kennedy A. Nutting C. Jakobs T. Cianni R. Notarianni E. Ofer A. et al. (2009) A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 27: 682–690.
32. Kujala E. Makitie T. Kivela T. (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44: 4651–4659.
33. Lebhati R. Cadiot G. Marmuse J. Vissuzaine C. Petegnief Y. Courillon-Mallet A. et al. (1997) False-positive somatostatin receptor scintigraphy due to an accessory spleen. J Nucl Med 38: 1979–1981.
34. Leporrier J. Maurel J. Chiche L. Bara S. Segol P. Launoy G. (2006) A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93: 465–474.
35. Leyvraz S. Spataro V. Bauer J. Pampallona S. Salmon R. Dorval T. et al. (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15: 2589–2595.
36. Lienard D. Ewalenko P. Delmotti J. Renard N. Lejeune F. (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52–60.
37. Lorigan J. Wallace S. Mavligit G. (1991) The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. AJR 157: 1279–1281.
38. Marinelli A. Vahrmeijer A. van de Velde C. (1998) Phase I / II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res 147: 83–94.
39. Masi G. Vasile E. Loupakis F. Cupini S. Fornaro L. Baldi G. et al. (2011) Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 103: 21–30.
40. Mavligit G. Charnsangavej C. Carrasco C. Patt Y. Benjamin R. Wallace S. (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260: 974–976.
41. McLaughlin C. Wu X. Jemal A. Martin H. Roche L. Chen V. (2005) Incidence of noncutaneous melanomas in the US Cancer 103: 1000–1007.
42. Miao N. Pingpank J. Alexander H. Steinberg S. Beresneva T. Quezado Z. (2008) Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 15: 815–823.
43. Moertel C. (1987) An odyessy in the land of small tumors. J Clin Oncol 5: 1502–1522.
44. Norheim I. Oberg K. Theodorsson-Norheim E. Lindgren P. Lundqvist G. Magnusson A. et al. (1987) Malignant carcinoid tumors. Ann Surg 206: 115–125.
45. Noter S. Rothbarth J. Pijl M. Keunen J. Hartgrink H. Tijl F. et al. (2004) Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 14: 67–72.
46. Peters S. Voelter V. Zografos L. Pampallona S. Popescu R. Gillet M. et al. (2006) Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17: 578–583.
47. Pingpank JR. (2010) Mephalan for colorectal metastases to the liver. Clin Adv Hematol Oncol 8: 175–7.
48. Pingpank J. Libutti S. Chang R. Wood B. Neeman Z. Kam A. et al. (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23: 3465–3474.
49. Ravikumar T. Pizzorno G. Bodden W. Marsh J. Strair R. Pollack J. et al. (1994) Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 12: 2723–2736.
50. Rosenbaum C. Verkooijen H. Lam M. Smits M. Koopman M. van Seeters T. et al. (2013) Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J Nucl Med 54: 1890–1895.
51. Rothbarth J. Pijl M. Vahrmeijer A. Hartgrink H. Tijl F. Kuppen P. et al. (2003) Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 90: 1391–1397.
52. Rothenberg M. Cox J. Butts C. Navarro M. Bang Y. Goel R. et al. (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19: 1720–1726.
53. Sanoff H. Sargent D. Campbell M. Morton R. Fuchs C. Ramanathan R. et al. (2008) Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26: 5721–5727.
54. Sato T. Eschelman D. Gonsalves C. Terai M. Chervoneva I. McCue P. et al. (2008) Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 26: 5436–5442.
55. Schwemmle K. Link K. Rieck B. (1987) Rationale and indications for perfusion in liver tumors: current data. World J Surg 11: 534–540.
56. Seregard S. Kock E. (1995) Prognostic indicators following enucleation for posterior uveal melanoma. Acta Opthalmol Scand 73: 340–344.
57. Singh A. Topham A. (2003) Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 110: 956–961.
58. Skibba J. Quebbeman E. (1986) Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg 121: 1266–1271.
59. Stehlin J. (1969) Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 129: 305–308.
60. Tzeng C. Aloia T. (2013) Colorectal liver metastases. J Gastrointest Surg 17: 195–201.
61. van Iersel L. Gelderblom H. Vahrmeijer A. van Persijn van Meerten E. Tijl F. Putter H. et al. (2008 a) Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19: 1127–1134.
62. van Iersel L. Hoekman E. Gelderblom H. Vahrmeijer A. van Persijn van Meerten E. Tijl F. et al. (2008 b) Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 15: 1891–1898.
63. van Iersel L. Koopman M. van de Velde C. Mol L. van Persijn van Meerten E. Hartgrink H. et al. (2010) Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol 21: 1662–1667.
64. van Cutsom E. Bajetta E. Valle J. Kohne C. Hecht J. Moore M. et al. (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29: 2004–2010.
65. Whitney R. Valek V. Fages J. Garcia A. Narayanan G. Tatum C. et al. (2011) Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist 16: 594–601.
66. Yang T. Chua T. Morris D. (2012) Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surg Oncol 21: 299–308.
67. Zeh H. III Brown C. Holtzman M. Egorin M. Holleran J. Potter D. et al. (2009) A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 16: 385–394.